Core Viewpoint - The company, Jianmin Group, has received approval from the National Medical Products Administration for clinical trials of its nasal medication, indicating a significant step in the development of a treatment for acute sinusitis [1] Company Summary - Jianmin Group (stock code: 600976) announced on August 14 that it has obtained the "Drug Clinical Trial Approval Notice" for its product, Nasal Congestion Relief Granules [1] - The approved indication for this medication is acute sinusitis, which suggests potential market opportunities in addressing this common health issue [1]

Core Viewpoint - The company will hold an investor briefing on August 21, 2025, to discuss its 2025 semi-annual report and address common investor concerns [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for August 21, 2025, from 15:00 to 16:00 [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [4][5]. - Investors can submit questions from August 14 to August 20, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key participants in the meeting will include the company's Chairman, independent directors, President, CFO, and Secretary of the Board [4]. Group 3: Participation Method - Investors can join the briefing online on the specified date and time, and the company will respond to questions in real-time [5]. - Investors are encouraged to pre-submit questions to facilitate the discussion during the meeting [5]. Group 4: Contact Information - For inquiries, investors can contact the company representatives via phone or email [6][7].

Core Viewpoint - Jianmin Group (600976) announced plans to hold a semi-annual performance briefing on August 21, 2025, from 15:00 to 16:00 [1] Summary by Relevant Sections - Company Announcement - Jianmin Group will conduct a semi-annual performance briefing in 2025 [1]

Core Viewpoint - The company will hold a half-year performance briefing on August 21, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in interactive communication [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for August 21, 2025, from 15:00 to 16:00 [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [2][3]. - Investors can submit questions from August 14 to August 20, 2025, through the Shanghai Stock Exchange Roadshow Center website or via the company's email [2][3]. Group 2: Participants - Key participants in the meeting will include the company's Chairman, independent directors, President, CFO, and Secretary of the Board [2][3]. Group 3: Investor Participation - Investors can participate online during the meeting and will receive timely responses to their questions [3]. - The company encourages investors to actively engage in the performance briefing and will provide access to the meeting's main content afterward [3].

证券代码：600976 证券简称：健民集团 公告编号：2025-030 健民药业集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 8 月 21 日(星期四)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 健民药业集团股份有限公司（以下简称"公司"）将于 2025 年 8 月 20 日发 布公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 8 月 21 日下午 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者普遍关心的问题进行交流。 一、说明会类型 投资者可于 2025 年 8 月 14 日(星期四)至 8 月 20 日(星期三)16:00 ...

Group 1 - The core viewpoint of the news is that Jianmin Group's recent financial performance shows a decline in revenue but an increase in net profit, indicating potential resilience in profitability despite revenue challenges [1] - As of August 5, 2025, Jianmin Group's stock closed at 42.11 yuan, down 0.64%, with a turnover rate of 2.25% and a trading volume of 34,400 hands, amounting to a transaction value of 145 million yuan [1] - The latest quarterly report indicates that the company's total operating revenue was 892 million yuan, a year-on-year decrease of 8.04%, while the net profit attributable to shareholders was 110 million yuan, a year-on-year increase of 10.70% [1] Group 2 - The company has a current ratio of 1.646, a quick ratio of 1.456, and a debt-to-asset ratio of 40.15%, reflecting a stable liquidity position [1] - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 1.533986 billion yuan [1] - The company has made investments in 30 enterprises and has participated in 5,000 bidding projects, showcasing its active engagement in the market [2]

8月4日，沪深两融数据显示，健民集团上周累计获融资净买入额1613.45万元，居两市第462位，上周融 资买入额8509.16万元，偿还额6895.71万元。 天眼查商业履历信息显示，健民药业集团股份有限公司，成立于1993年，位于武汉市，是一家以从事医 药制造业为主的企业。企业注册资本15339.86万人民币，实缴资本4211.2614万人民币。公司法定代表人 为汪俊。 通过天眼查大数据分析，健民药业集团股份有限公司共对外投资了30家企业，参与招投标项目5000次， 知识产权方面有商标信息526条，专利信息241条，此外企业还拥有行政许可313个。 来源：金融界 健民集团所属概念板块包括：中药、湖北板块、内贸流通、沪股通、融资融券、流感、独家药品、中药 概念。 资金流方面，健民集团近5日主力资金流入3011.59万元，区间涨幅3.75%；近10日主力资金流入2199.53 万元，区间涨幅1.71%。 ...

Financial Performance - As of August 1, 2025, Jianmin Group's stock closed at 42.66 yuan, up 2.42%, with a turnover rate of 3.42% and a trading volume of 52,400 lots, amounting to 222 million yuan [1] - For Q1 2025, the company reported total revenue of 892 million yuan, a year-on-year decrease of 8.04%, while net profit attributable to shareholders was 110 million yuan, an increase of 10.70% [1] - The company's non-recurring net profit was 103 million yuan, reflecting a year-on-year growth of 13.92% [1] - The liquidity ratios are as follows: current ratio at 1.646, quick ratio at 1.456, and debt-to-asset ratio at 40.15% [1] Capital Flow - On the reporting day, the net inflow of main funds was 21.48 million yuan, accounting for 9.69% of the total transaction amount [1] - Large orders saw a net inflow of 15.24 million yuan, representing 6.88% of the transaction amount, while small orders experienced a net outflow of 14.74 million yuan, accounting for 6.65% [1] Company Overview - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is located in Wuhan, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.533986 billion yuan and a paid-in capital of 421.12614 million yuan [2] - The legal representative of the company is Wang Jun [2] Investment and Intellectual Property - Jianmin Pharmaceutical has made investments in 30 enterprises and participated in 5,000 bidding projects [2] - The company holds 526 trademark registrations and 241 patent applications, along with 313 administrative licenses [2]

Market Overview - The Shanghai Composite Index closed at 3559.95 points, slightly down by 0.37%, with a total trading volume of 161.99 billion yuan [1] - A total of 55 A-shares have surpassed their annual line, indicating a positive market sentiment [1] Notable Stocks - The stocks with the highest deviation rates above the annual line include: - JieJia WeiChuang (300724) with a deviation rate of 14.08% and a daily increase of 20.00% [1] - AiLuo Energy (688717) with a deviation rate of 3.52% and a daily increase of 4.02% [1] - KuaiKe Electronics (301278) with a deviation rate of 3.30% and a daily increase of 3.57% [1] - Other stocks that have just crossed the annual line with smaller deviation rates include: - FuLing ZhaCai (涪陵榨菜) and TongWei Co. (通威股份) [1] Trading Data - The trading data for stocks that broke the annual line includes: - JieJia WeiChuang: Latest price 66.19 yuan, turnover rate 16.84% [1] - AiLuo Energy: Latest price 57.94 yuan, turnover rate 5.03% [1] - KuaiKe Electronics: Latest price 35.11 yuan, turnover rate 6.66% [1] - Additional stocks with notable performance include: - XinDian Software (688232) with a 4.61% increase and a deviation rate of 3.08% [1] - DongWang Times (600052) with a 4.47% increase and a deviation rate of 2.69% [1]

Group 1: Report Overview - The report is about a research on Jianmin Group in the traditional Chinese medicine industry, with a research date of July 1, 2025 [1][2] Group 2: Research Basic Information - The research object is Jianmin Group, belonging to the traditional Chinese medicine industry, and the reception time was on July 1, 2025. The company's reception personnel included the company's director and president Wang Jun, board secretary Zhou Jie, securities affairs representative Cao Hong, and securities affairs assistant Wang Miao [17] Group 3: Detailed Research Institutions - The research institution is Liuhe Investment, a fund management company [20] Group 4: Main Content Product Sales - In 2025, the company optimized its marketing assessment system, advancing from "net sales assessment" to "net sales + profit". It overcame factors like consumption decline and reduced pharmacy foot - traffic in Q1 and achieved growth in pharmaceutical industry sales revenue. Longmu Zhuanggu Granules saw increased sales revenue and improved sales structure, while Biantong Capsules and Jianpi Shengxue Granules maintained good momentum. Hospital - line product sales were stable, and new product sales grew [22] Emerging Business - The company's traditional Chinese medicine diagnosis and treatment and big - health business are emerging. The traditional Chinese medicine diagnosis and treatment business developed healthily, with one new clinic opened in H1 and a total of four clinics in operation in Hanyang, Hankou, Wuchang, and Optics Valley. The big - health business focused on children's healthy growth, increasing core variety cultivation and differentiated product development [23] Innovative Traditional Chinese Medicine Sales - Since 2021, the company has successively obtained approvals for three innovative drugs. In 2025, it accelerated the commercialization of new products like Xiao'er Zibei Xuanfei Syrup and Qirui Weishu Capsules, with smooth market development. Xiao'er Niuhuang Tuire Plaster was newly approved, and its listing preparations are on schedule and will participate in this year's medical insurance negotiation. The company also increased R & D investment, advanced new drug projects, and optimized its product pipeline [24][25] Future Development Plan - The company will continue to focus on the core business of traditional Chinese patent medicine manufacturing, accelerate the incubation of emerging businesses, and achieve the "1 + N" strategic goal. Specific strategic measures are detailed in the company's "2024 Annual Report" and "June 2025 Investor Relations Activity Record" [26] Advertising and Marketing - As an OTC brand pharmaceutical company, it will strengthen brand power, create "Longmu" children's medicine brand and "Jianmin" chronic disease/family - essential medicine brand. It uses multiple advertising channels such as long - form videos, short - form videos, variety shows, CCTV, and elevator media, with advertising volume similar to last year [27] Marketing System Reform - In 2024, the company carried out a comprehensive marketing system reform. In 2025, it added profit contribution assessment on the basis of net sales assessment. It optimized the organizational structure, promoted digital construction, and reduced terminal inventory. As of the end of 2024, the channel inventory of Longmu Zhuanggu Granules on the OTC line and major products on the prescription line had basically returned to a reasonable level [28] Impact of Chinese Herbal Medicine Price - The overall decline in Chinese herbal medicine prices is beneficial for the company's cost reduction and profit improvement. The company's manufacturing center uses multiple procurement models and strengthens cooperation with upstream suppliers to ensure stable raw material supply [29][30]